Cleveland BioLabs, Inc. Stock Nasdaq
Equities
US1858601032
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2021 | Cleveland Biolabs : Cytocom Changing Name to Statera BioPharma | MT |
2021 | Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 | CI |
Financials (USD)
Sales 2020 | - | Sales 2021 | 1.49 | Capitalization | 73.82M |
---|---|---|---|---|---|
Net income 2020 | -12M | Net income 2021 | -102M | EV / Sales 2020 * | - |
Net Debt 2020 | 1.41M | Net Debt 2021 | 14.28M | EV / Sales 2021 | 59,246,379 x |
P/E ratio 2020 * |
-
| P/E ratio 2021 |
-0.79
x | Employees | - |
Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 100% |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.86B | |
+45.15% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |